Vir Biotechnology (Vir Biotechnology) EBIT per Share : $-5.10 (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Vir Biotechnology EBIT per Share?

Vir Biotechnology's EBIT per Share for the three months ended in Dec. 2023 was $-1.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.10.

During the past 12 months, the average EBIT per Share Growth Rate of Vir Biotechnology was -182.60% per year. During the past 3 years, the average EBIT per Share Growth Rate was -27.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Vir Biotechnology's EBIT per Share or its related term are showing as below:

VIR' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.6 Med: -35.3 Max: -27
Current: -27

During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Vir Biotechnology was -27.00% per year. The lowest was -43.60% per year. And the median was -35.30% per year.

VIR's 3-Year EBIT Growth Rate is ranked worse than
79.54% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs VIR: -27.00

Vir Biotechnology's EBIT for the three months ended in Dec. 2023 was $-139.02 Mil.

Vir Biotechnology EBIT per Share Historical Data

The historical data trend for Vir Biotechnology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vir Biotechnology EBIT per Share Chart

Vir Biotechnology Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-5.86

-2.49

3.15

6.18

-5.10

Vir Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-1.11	-1.07	-1.61	-1.39	-1.03

Vir Biotechnology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Vir Biotechnology's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-684.305	/	134.131
=	-5.10

Vir Biotechnology's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-139.016	/	134.614
=	-1.03

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.10

Vir Biotechnology (NAS:VIR) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Vir Biotechnology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Vir Biotechnology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vir Biotechnology (Vir Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vir Biotechnology Inc (NAS:VIR) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

499 Illinois Street, Suite 500, San Francisco, CA, USA, 94158

Website

https://www.vir.bio

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Executives

Svf Endurance (cayman) Ltd	10 percent owner	C/O WALKERS CORPORATE LIMITED, 27 HOSPITAL ROAD, GEORGE TOWN E9 KY1-9008
Vicki L Sato	director	940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451
Phillip Pang	officer: Chief Medical Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Steven J. Rice	officer: Chief Administrative Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Saira Ramasastry	director	501 CANAL BLVD., RICHMOND CA 94804
Backer Marianne De	officer: Chief Executive Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Ann M. Hanly	officer: Chief Technology Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Sung Lee	officer: Chief Financial Officer	7000 MARINA BLVD, BRISBANE CA 94005
Johanna Friedl-naderer	officer: Chief Business Officer, Global	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
George A Scangos	director, officer: President and CEO	C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Howard Horn	officer: CFO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Charles Elliott Sigal	director	32 BREARLY ROAD, PRINCETON NJ 08540
Herbert Virgin	officer: EVP, Research & CSO	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Janet Napolitano	director	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Robert J More	director	680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001